Bicycle Therapeutics trades below net cash, reflecting market skepticism on future cash burn and delayed commercialization.
Finally, current quality-of-life tools do not fully capture the patient experience. Emerging approaches incorporating patient ...
(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers poster session. Dr. David Cade presented LUTEON, an ongoing phase III trial ...